CHICAGO – July 10, 2018 – First Analysis, a leading mid-stage venture capital investor, has closed on its 13th fund (First Analysis Fund XII+) at $91 million in committed capital. With the new fund, First Analysis will continue its 33-year track record in technology and healthcare investing. To date, the fund has invested in three companies.
About First Analysis
First Analysis is a leading venture capital investor, now in its fourth decade of venture investing and investing from its 13th fund. We use our integrative research process to uncover and leverage the best opportunities in emerging high-growth segments in technology and healthcare for the benefit of the investors and growth companies we serve, as well as our broader society and environment. The integrative research process drives success by unifying naturally divergent perspectives, capabilities, skillsets, and relationships. The process integrates 1) dynamic investment research on thousands of publicly traded and privately held companies with 2) thousands of relationships among executives, investors, and other key participants in our focus areas, yielding a deep, comprehensive understanding of each segment’s near-term and long-term potential. We help established companies become leaders in large markets, funding growth plans and working closely with management in areas including strategy, recruitment, sales and marketing, and corporate development. Our flexible approach targets investing $3-10 million as lead investor or as a syndicate partner who brings valuable perspective.
For more information, please contact:
To download a pdf version of this announcement, please follow the link below:
First Analysis closes on new $91 million private growth equity fund - July 2018